论文部分内容阅读
米非司酮是一种受体水平孕激素拮抗剂,自20世纪80年代以来,逐渐在临床上被推广并应用于妇产科疾病的治疗中。米非司酮的应用最早主要是在终止早期妊娠方面,并取得了显著的临床效果[1]。随着医学界对米非司酮研究的不断深入与发展,使该药物在妇产科的其他方面也得到了推广,如在异位妊娠、终止中晚期妊娠或死胎引产、紧急避孕、子宫内膜异位症、更年期功血、子宫腺肌病、子宫肌瘤、乳腺癌等方面的治疗。本文
Mifepristone is a receptor-level progestin antagonist. Since the 1980s, mifepristone has gradually been applied clinically in the treatment of obstetrics and gynecology diseases. The earliest application of mifepristone is mainly in the termination of early pregnancy, and achieved significant clinical results [1]. With the deepening of medical research on mifepristone, the drug has also been promoted in other aspects of obstetrics and gynecology, such as ectopic pregnancy, termination of late pregnancy or stillbirth induction, emergency contraception, intrauterine Membranous ectopic, menopause dysfunctional uterine bleeding, adenomyosis, uterine fibroids, breast cancer and other aspects of treatment. This article